Skip to main content
Fig. 9 | Journal of Neuroinflammation

Fig. 9

From: Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice

Fig. 9

Ibrutinib significantly reduced LPS-stimulated microglial and astrocyte activation in wild-type mice. a Wild-type mice were injected with ibrutinib (10 mg/kg, i.p.) or vehicle (10% DMSO, i.p.) daily for 3 days, followed by injection with LPS (10 mg/kg, i.p.) or PBS. Three hours after the injection of LPS or PBS, immunohistochemistry was conducted with an anti-Iba-1 antibody. b, c Quantification of the data shown in a (cortex: vehicle, n = 5 mice; LPS, n = 5 mice; ibrutinib+LPS, n = 5 mice; and hippocampus: vehicle, n = 5 mice; LPS, n = 5 mice; ibrutinib+LPS, n = 5 mice). d Wild-type mice were injected with ibrutinib (10 mg/kg, i.p.) or vehicle (10% DMSO, i.p.) daily for 3 days, followed by injection with LPS (10 mg/kg, i.p.) or PBS. Three hours after the injection of LPS or PBS, immunohistochemistry was conducted with an anti-GFAP antibody. e, f Quantification of the data shown in d (cortex: con, n = 5 mice; LPS, n = 5 mice; ibrutinib+LPS, n = 5 mice; and hippocampus: con, n = 5 mice; LPS, n = 5 mice; ibrutinib+LPS, n = 5 mice). *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page